Listar por autor "Malik, Fady I."

Mostrando ítems 1-4 de 4

    • Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial 

      Felker, G. Michael; Solomon, Scott D.; Claggett, Brian; Díaz, Rafael; McMurray, John J.V.; Metra, Marco; Anad, Inder; Crespo-Leiro, María Generosa; Dahlström, Ulf; Goncalvesova, Eva; Howlett, Jonathan G.; MacDonald, Peter; Parkhomenko, Alexander; Tomcsányi, János; Abbasi, Siddique A.; Heitner, Stephen B.; Hucko, Thomas; Kupfer, Stuart; Malik, Fady I.; Teerlink, John R. (American Medical Association, 2021-10-13)
      [Abstract] Importance: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant ...

    • Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Li, J.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Varin, Claire; Honarpour, N.; Abbasi, Siddique A.; Malik, Fady I.; Kurtz, Christopher E. (Massachusetts Medical Society, 2020-11-13)
      [Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular ...

    • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials 

      Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E. (Willey Online Library, 2020-09-20)
      [Abstract] Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...

    • Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial 

      Pabon, Maria; Cunningham, Jon; Claggett, Brian; Felker, Michael; McMurray, John J.V.; Metra, Marco; Díaz, Rafael; Wang, Xiaowen; Arias-Mendoza, Alexandra; Bonderman, Diana; Crespo-Leiro, María Generosa; Fonseca, Cândida; Goncalvesova, Eva; Lund, Mayanna; O’Meara, Eileen; Sliwa-Hahnle, Karen; Malik, Fady I.; Solomon, Scott D.; Teerlink, John R. (Elsevier on behalf of the American College of Cardiology Foundation, 2023-10-11)
      [Abstract] Background: Women with heart failure with reduced ejection fraction (HFrEF) receive less guideline-recommended therapy and experience worse quality of life than men. Objectives: The authors sought to assess ...